Finland· FI-REL-REL61566
Obgemsa
A vibegron product containing vibegron, registered in Finland by Pierre Fabre Medicament. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Vibegron is registered in 13 of 19 countries.
Countries holding a registration under ATC G04BD15 (vibegron), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Vibegron · ATC G04BD15
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vibegron costs, country by country.
Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vibegron · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.76
The record
At a glance
Fimea (Finland)- Active substance
- Vibegron
- Manufacturer
- Pierre Fabre Medicament
- Country
- Finland (FI)
- ATC code
- G04BD15
- ATC class
- Vibegron
- Defined daily dose
- 75 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for vibegron.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vibegron · interactions on record
2 records
- 2 moderate
Most severe, free to view
- TrospiumA03AB20moderate
- TrospiumG04BD09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vibegron in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOBGEMSAPIERRE FABRE MEDICAMENT, Lavaur
- SwitzerlandObgemsa 75 mg, FilmtablettenPierre Fabre Pharma SA
- FranceOBGEMSA 75 mg, comprimé pelliculéPIERRE FABRE MEDICAMENT
- IrelandObgemsa 75 mg film-coated tabletsPierre Fabre Medicament
- IcelandObgemsaPierre Fabre Medicament
- NetherlandsObgemsa 75 mg filmomhulde tablettenPierre Fabre Medicament
- NorwayObgemsaPierre Fabre Medicament
- PolandObgemsaPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Obgemsa
- Liechtenstein · Obgemsa
- Norway · Obgemsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df51bed5-69af-42df-b6fc-eb51f31d1107 GET /v1/drugs/df51bed5-69af-42df-b6fc-eb51f31d1107?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "75",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "75 mg",
"atc_label": "vibegroni",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1822/001-006",
"fimea_rel_id": "REL61566",
"authorised_at": "2024-06-27"
}See everything about vibegron.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.